SMMT Summit Therapeutics PLC
Company Analysis
Latest News
🟢 Summit Therapeutics is trading 10% up today after partner Akeso reported positive HARMONi-GI1 results
Summit Therapeutics is trading 10.25% up now at $14.73 after partner Akeso reported positive topline HARMONi-GI1 results on August 26, 2026. - Phase III...
Summit's Lung Cancer Drug Posts Strong Trial Data, but Can a $10 Billion Valuation Hold Without Proof It Extends Lives?
Shares of Summit Therapeutics surged 10.3% to $14.73 after The Lancet Oncology published full results from the company's flagship HARMONi trial, confirming...
🟢 Summit Therapeutics is trading 10.25% up in pre-market after positive Phase III HARMONi results
Summit Therapeutics is trading 10.25% up in pre-market at $14.73 after the August 25, 2026 publication of positive Phase III HARMONi results in The Lancet...
🟢 Summit Therapeutics is trading 4.5% up in pre-market after statistically significant HARMONi progression-free-survival improvement
Summit Therapeutics is trading 4.5% up in pre-market at $13.96 after reporting statistically significant progression-free-survival improvement from ivonescimab...
🟢 Summit Therapeutics is trading 4.9% up today after significant HARMONi trial progression-free-survival improvement
Summit Therapeutics is trading $13.35 (+4.87%) after announcing significant progression-free-survival improvement for ivonescimab plus chemotherapy versus...
🔴 Summit Therapeutics is trading 5% down today
Summit Therapeutics is trading 5.47% down now at $12.44, while the specific intraday trigger remains unclear. - No confirmed company-specific announcement has...
🟢 Summit Therapeutics is trading 5% up today in an unexplained intraday rebound
Summit Therapeutics is trading 5.03% up now at $13.13, with no confirmed company-specific catalyst identified. - No announcement, filing, earnings release, or...
🔴 Summit Therapeutics falls 4.1% — Biotech Sector Cools Off After Moderna-Sparked Rally
With Biotech (XBI) down 2.5%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector is experiencing a pullback after a...
🔴 Summit Therapeutics is trading 7.23% down today after further declines from August 13 and 14
Summit Therapeutics is trading 7.23% down at $12.38 after early-session selling extended declines from August 13 and August 14. - No reliable company-specific...
🔴 Summit Therapeutics is trading 4.07% down today after opening-market selling extended August 13 decline
Summit Therapeutics is trading 4.07% down at $13.43 after opening-market selling extended the August 13 decline. - No reliable company-specific catalyst...
🔴 Summit Therapeutics is trading 5.83% down today despite Akeso’s third NMPA approval
Summit Therapeutics is trading 5.83% down now at $14.22, with no reliable company-specific negative catalyst identified for the August 13 decline. - Partner...
Summit Partner Wins China Approval for Ivonescimab, Topping Standard PD-1 Therapy
Summit Therapeutics announced that partner Akeso Inc. received marketing authorization from China’s National Medical Products Administration. The approval...
🟢 Summit Therapeutics is trading 5% up today with no clear company-specific catalyst
Summit Therapeutics is trading at $15.64, up 5.18%, with no clearly identified company-specific announcement explaining the August 11, 2026 advance. - The...
🟢 Summit Therapeutics is trading 4.48% up today with no clear catalyst
Summit Therapeutics is trading at $14.59 (+4.48%) with no clear catalyst identified. - No new company announcement, clinical update, financing, or regulatory...
Summit Therapeutics Expands Ivonescimab Program with Phase II/III Bladder Cancer Trial
Summit Therapeutics announced the expansion of its global clinical development program for its investigational bispecific antibody, ivonescimab, into...
🟢 Summit Therapeutics is trading 4.5% up today amid a broad risk-on rally in U.S. equities
Summit Therapeutics is trading 4.5% up at $13.63, moving in line with a broad risk-on rally across U.S. equities despite a lack of company-specific news. •...
🟢 Summit Therapeutics is trading 4.3% up today amid a broader biotech and Nasdaq recovery
Summit Therapeutics is trading at $13.35 (+4.26%) as the stock rebounds from recent biotech weakness and a broader market shift toward risk-on sentiment. •...
🟢 Summit Therapeutics is trading 4.1% up today on a broad risk rebound following recent biotech sector weakness
Summit Therapeutics is trading at $13.07 (+4.14%) as the stock stages a sharp recovery from a volatile two-day decline and a close of $12.55 on July 28. • The...
🔴 Summit Therapeutics is trading 5% down today as focus shifts to ivonescimab spending and PDUFA risk
Summit Therapeutics is trading at approximately $12.45 (5% down), extending a multi-day slide after its July 23, 2026, earnings update shifted investor focus...
🔴 Summit Therapeutics is trading 8.9% down today after wider Q2 loss and ivonescimab data update
Summit Therapeutics is trading at $13.65 (8.9% down) after reporting a wider second-quarter loss and providing updated Phase III HARMONi data for...